CN103288757B - 6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法 - Google Patents
6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法 Download PDFInfo
- Publication number
- CN103288757B CN103288757B CN201310181150.2A CN201310181150A CN103288757B CN 103288757 B CN103288757 B CN 103288757B CN 201310181150 A CN201310181150 A CN 201310181150A CN 103288757 B CN103288757 B CN 103288757B
- Authority
- CN
- China
- Prior art keywords
- amino
- hydroxyl
- dihydroquinazoline
- preparation
- ketone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 238000006396 nitration reaction Methods 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 11
- -1 3-amino-4-hydroxybenzoic acid ester Chemical class 0.000 claims abstract description 6
- 238000006722 reduction reaction Methods 0.000 claims abstract description 6
- 238000010719 annulation reaction Methods 0.000 claims abstract description 4
- 239000003054 catalyst Substances 0.000 claims abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims description 12
- LZKGFGLOQNSMBS-UHFFFAOYSA-N 4,5,6-trichlorotriazine Chemical compound ClC1=NN=NC(Cl)=C1Cl LZKGFGLOQNSMBS-UHFFFAOYSA-N 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- KHFJTHCIQARPKD-UHFFFAOYSA-N 3-amino-4-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(O)C(N)=C1 KHFJTHCIQARPKD-UHFFFAOYSA-N 0.000 claims description 4
- MRBKRZAPGUCWOS-UHFFFAOYSA-N 3-amino-4-hydroxybenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1O MRBKRZAPGUCWOS-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- PPNKDDZCLDMRHS-UHFFFAOYSA-N dinitrooxybismuthanyl nitrate Chemical compound [Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PPNKDDZCLDMRHS-UHFFFAOYSA-N 0.000 claims description 4
- 229910017604 nitric acid Inorganic materials 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960001701 chloroform Drugs 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 230000000802 nitrating effect Effects 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 10
- 238000010511 deprotection reaction Methods 0.000 abstract description 3
- 125000000524 functional group Chemical group 0.000 abstract description 2
- BWKDAAFSXYPQOS-UHFFFAOYSA-N Benzaldehyde glyceryl acetal Chemical compound O1CC(O)COC1C1=CC=CC=C1 BWKDAAFSXYPQOS-UHFFFAOYSA-N 0.000 abstract 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- MGXZZMANWZFPEE-UHFFFAOYSA-N 5-amino-4-hydroxy-2-nitrobenzamide Chemical compound [N+](=O)([O-])C1=C(C(=O)N)C=C(C(=C1)O)N MGXZZMANWZFPEE-UHFFFAOYSA-N 0.000 description 5
- 230000000118 anti-neoplastic effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- RGPUVZXXZFNFBF-UHFFFAOYSA-K diphosphonooxyalumanyl dihydrogen phosphate Chemical compound [Al+3].OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O RGPUVZXXZFNFBF-UHFFFAOYSA-K 0.000 description 3
- 239000005461 Canertinib Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229950002826 canertinib Drugs 0.000 description 2
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 2
- 229950002205 dacomitinib Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 0 CC(C=C(C(C=C)=*)N)=C(C)N Chemical compound CC(C=C(C(C=C)=*)N)=C(C)N 0.000 description 1
- KRWBRJBRUJSXJM-UHFFFAOYSA-N CC(CC(N)=C(C1)N)(C1C(NC)=O)NC Chemical compound CC(CC(N)=C(C1)N)(C1C(NC)=O)NC KRWBRJBRUJSXJM-UHFFFAOYSA-N 0.000 description 1
- 239000005785 Fluquinconazole Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011973 solid acid Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明揭示了一种6-氨基-7-羟基-3，4-二氢喹唑啉-4-酮的制备方法，其包括如下步骤：以3-氨基-4-羟基苯甲酸或3-氨基-4-羟基苯甲酸酯或3-氨基-4-羟基苯甲酰胺为原料，依次经硝化反应、还原反应以及成环反应，制备所述6-氨基-7-羟基-3，4-二氢喹唑啉-4-酮(I)。该工艺路线通过新型催化剂的使用，使硝化反应的选择性更强。同时，通过省略官能团的保护和脱保护等反应步骤，使得整个过程更为简洁、收率更高，更加经济环保。
Description
技术领域
本发明属于有机合成路线设计及其原料药和中间体制备技术领域，特别涉及一种用于替尼类抗肿瘤药合成所需中间体6-氨基-7-羟基-3，4-二氢喹唑啉-4-酮的制备方法。
背景技术
蛋白酪氨酸激酶(PTK)是最常见的生长因子受体，通过阻断酪氨酸激酶破坏肿瘤细胞的信号传递，从而达到抗肿瘤的目的。受体酪氨酸激酶抑制剂包括单靶点酪氨酸激酶抑制剂和多靶点酪氨酸激酶抑制剂。目前研究比较活跃的替尼类抗肿瘤药物就属于多靶点酪氨酸激酶抑制剂，具有抗***癌、肺癌、胃癌、血癌、乳腺癌、肠癌、胰腺癌和胆癌等作用。
分析替尼类药物的分子结构，有很大一部分是以喹唑啉为核心的小分子化合物，如吉非替尼、厄洛替尼、埃克替尼和凡德他尼等已经在临床上表现出了很好的生物活性。特别地，新近上市的阿法替尼(Afatinib)和正在临床研究之中的卡奈替尼(Canertinib)、达克米替尼(Dacomitinib)则均具有6-位羟基和7-位氨基的喹唑啉结构。
已经公开的上述替尼类抗肿瘤药的制备主要有以下两类方法：世界专利第WO0250043A1号和WO03094921A2号分别报道了以4-氯-6-氨基-7-氟喹唑啉(V)和4-氯-6-氨基-7-甲氧基喹唑啉(VI)为起始原料的制备方法。
另外，利用6，7-位取代的3，4-二氢喹唑啉-4-酮通过氯化，形成的氯代物中间体(VIII)与苯胺衍生物发生4-位缩合反应，可方便地制备替尼类抗肿瘤药物的目标化合物。
由此可见，6-氨基-7-羟基-3，4-二氢喹唑啉-4-酮(I)将会成为制备上述6-氨基-7羟基喹唑啉衍生物的替尼类抗肿瘤药物的又一重要中间体。现有技术对该中间体的合成，必须通过硝化、还原、成环等步骤。而现有硝化技术中发烟硝酸和浓硫酸的使用，使得原料中裸露的氨基和羟基发生氧化、消去或取代等副反应，所以实际操着过程中，不得不对氨基和羟基进行必要的保护，而在完成硝化、还原等步骤后又需要脱除这些保护基团，从而使反应步骤增多，总收率降低。同时，现行硝化反应的选择性不强，易产生污染，不适应工业化要求。如果能开发出一条简单快捷、成本低廉且适合工业化制备6-氨基-7-羟基-3，4-二氢喹唑啉-4-酮(I)的制备方法，对于基于喹唑啉结构的抗肿瘤药物如阿法替尼(Afatinib)、卡奈替尼(Canertinib)和达克米替尼(Dacomitinib)等的生产和制备具有非常重要的现实意义。
发明内容
本发明的目的在于针对现有技术中的上述缺陷，提供一种改进的6-氨基-7-羟基-3，4-二氢喹唑啉-4-酮的制备方法，特别是通过固体酸催化的硝化反应，增强了硝化反应的活性和选择性，避免了氨基和羟基的保护和脱保护过程，使整个制备过程的原子经济性、工艺简洁性和环境友好性得到显著的提高。
为了实现上述目的，本发明所提供的主要技术方案如下：一种制备6-氨基-7-羟基-3，4-二氢喹唑啉-4-酮(I)的方法，
其特征在于所述制备方法包括如下步骤：以式(II)所示的3-氨基-4-羟基苯甲酸或3-氨基-4-羟基苯甲酸酯或3-氨基-4-羟基苯甲酰胺为原料，依次经硝化反应、还原反应以及成环反应，制备6-氨基-7-羟基-3，4-二氢喹唑啉-4-酮(I)。
此外，本发明还包括如下附属技术方案：
当所述化学式(II)中的R为羟基(OH)时，原料为3-氨基-4-羟基苯甲酸；当R为烷氧基(OR’)时，原料为3-氨基-4-羟基苯甲酸酯；当R为胺基(NH2)时，原料为3-氨基-4-羟基苯甲酰胺。
当所述R为烷氧基(OR’)时，其中的烷基R’为甲基、乙基、丙基、烯丙基、异丙基、正丁基、叔丁基、环己基、苄基或苯环上取代的苄基，优选甲基或乙基。
所述硝化反应的硝化剂为浓硝酸、硝酸铜、硝酸铋或硝酸锌，优选浓硝酸或硝酸锌。
所述硝化反应的催化剂为硫酸/三聚氰胺甲醛树脂、硫酸/聚乙烯吡咯烷酮(PVP)、硫酸/二氧化硅、三氯均三嗪(TCT)或磷酸二氢铝，优选三氯均三嗪或磷酸二氢铝。
所述硝化反应的催化剂用量为起始原料(II)物质量的1-10％，优选1-5％。
所述硝化反应的溶剂为二氯甲烷、氯苯、三氯甲烷、1，2-二氯甲烷、乙腈或水，优选乙腈或水。
所述硝化反应的温度为0-120℃，优选20-30℃。
所述6-氨基-7-羟基-3，4-二氢喹唑啉-4-酮为用于替尼类抗肿瘤药合成所需中间体。
相比于现有技术，本发明所涉及的替尼类抗肿瘤药物中间体6-氨基-7-羟基-3，4-二氢喹唑啉-4-酮的制备方法，该工艺路线通过新型催化剂的使用，使硝化反应的选择性更强。同时，通过省略官能团的保护和脱保护等反应步骤，使得整个过程更为简洁、收率更高，更加经济环保。
具体实施方式
本发明的核心在于新的硝化反应技术的运用，而还原和成环反应均为公知技术。下面通过数个具体的制备过程和方法对关键的硝化技术方案作进一步非限制性说明。
实施例一：
室温下，于反应瓶中加入3-氨基-4-羟基-苯甲酸甲酯(II)(3.4g，20mmol)、硝酸锌(4.2g，22mmol)、三氯均三嗪(0.11g，3％eq)和乙腈25mL。搅拌反应3小时。用无水硫酸钠干燥，减压回收溶剂，剩余物用乙酸乙酯重结晶，得淡黄色固体2-硝基-4-羟基-5-氨基苯甲酸甲酯(III)3.5g，收率为82.5％。
实施例二：
室温下，于反应瓶中加入3-氨基-4-羟基-苯甲酸甲酯(II)(3.4g，20mmol)、硝酸(70％，2.7mL，30mmol)、磷酸二氢铝(0.07g，1％eq)和乙腈20mL。搅拌反应2小时。加入碳酸氢钠溶液调节pH至中性，加入乙酸乙酯萃取，有机相用水洗涤，无水硫酸钠干燥。减压回收溶剂，剩余物用乙酸乙酯重结晶，得淡黄色固体2-硝基-4-羟基-5-氨基苯甲酸甲酯(III)3.7g，收率为87.3％。
实施例三：
室温下，于反应瓶中加入3-氨基-4-羟基-苯甲酸(II)(3.1g，20mmol)、硝酸锌(4.2g，22mmol)、三氯均三嗪(0.11g，3％eq)和乙腈25mL。搅拌反应4小时。用无水硫酸钠干燥，减压回收溶剂，剩余物用乙醇重结晶，得淡黄色固体2-硝基-4-羟基-5-氨基苯甲酸(III)3.2g，收率为80.8％。
实施例四：
室温下，于反应瓶中加入3-氨基-4-羟基-苯甲酰胺(II)(3.1g，20mmol)、硝酸锌(4.2g，22mmol)、三氯均三嗪(0.11g，3％eq)和乙腈25mL。搅拌反应2小时。用无水硫酸钠干燥，减压回收溶剂，剩余物用甲醇重结晶，得淡黄色固体2-硝基-4-羟基-5-氨基苯甲酰胺(III)3.1g，收率为78.3％。
需要指出的是，上述实施例仅为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施，并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰，都应涵盖在本发明的保护范围之内。
Claims (7)
1.一种6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法，
其特征在于所述制备方法包括如下步骤：以3-氨基-4-羟基苯甲酸或3-氨基-4-羟基苯甲酸酯或3-氨基-4-羟基苯甲酰胺为原料，依次经硝化反应、还原反应以及成环反应，制备所述6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮(I)，其中所述硝化反应的催化剂为三氯均三嗪。
2.根据权利要求1所述6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法，其特征在于：当所述原料为3-氨基-4-羟基苯甲酸酯时，其中的酯基为甲基、乙基、丙基、烯丙基、正丁基、叔丁基、环己基、苄基或苯环上取代的苄基。
3.根据权利要求1所述6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法，其特征在于：所述硝化反应的硝化剂包括浓硝酸、硝酸铜、硝酸铋或硝酸锌。
4.根据权利要求3所述6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法，其特征在于：所述硝化反应的催化剂用量为所述原料物质量的1-10％。
5.根据权利要求4所述6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法，其特征在于：所述硝化反应的溶剂为二氯甲烷、氯苯、三氯甲烷、乙腈或水。
6.根据权利要求3所述6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法，其特征在于：所述硝化反应的温度为0-120℃。
7.根据权利要求1至6中任一项所述6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法，其特征在于：所述6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮为用于替尼类抗肿瘤药合成所需中间体。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310181150.2A CN103288757B (zh) | 2013-05-16 | 2013-05-16 | 6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法 |
| PCT/CN2014/076537 WO2014183560A1 (zh) | 2013-05-16 | 2014-04-30 | 阿法替尼及其中间体的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310181150.2A CN103288757B (zh) | 2013-05-16 | 2013-05-16 | 6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103288757A CN103288757A (zh) | 2013-09-11 |
| CN103288757B true CN103288757B (zh) | 2015-07-01 |
Family
ID=49090345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310181150.2A Active CN103288757B (zh) | 2013-05-16 | 2013-05-16 | 6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103288757B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693524A (zh) * | 2014-11-28 | 2016-06-22 | 浙江省化工研究院有限公司 | 一种硝基化合物的制备方法 |
| CN107226785B (zh) * | 2017-06-11 | 2019-08-30 | 长春工业大学 | 金刚烷苯乙烯类衍生物及其制备方法和应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015638A1 (en) * | 1998-09-14 | 2000-03-23 | Dr. Reddy's Research Foundation | An improved process for the preparation of thiazolidine-2,4-dione derivatives |
| JP2002293773A (ja) * | 2001-03-30 | 2002-10-09 | Sumika Fine Chemicals Co Ltd | キナゾリン誘導体の製造方法 |
| WO2003064399A1 (fr) * | 2002-01-28 | 2003-08-07 | Ube Industries, Ltd. | Procede de production de derive de quinazolin-4-one |
| CN101613356A (zh) * | 2009-07-23 | 2009-12-30 | 东南大学 | 喹唑啉类四环衍生物及制备方法和在制药中的应用 |
| CN102898384A (zh) * | 2012-08-14 | 2013-01-30 | 邓俐丽 | 制备吉非替尼的中间体及所述中间体的制备方法 |
-
2013
- 2013-05-16 CN CN201310181150.2A patent/CN103288757B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015638A1 (en) * | 1998-09-14 | 2000-03-23 | Dr. Reddy's Research Foundation | An improved process for the preparation of thiazolidine-2,4-dione derivatives |
| JP2002293773A (ja) * | 2001-03-30 | 2002-10-09 | Sumika Fine Chemicals Co Ltd | キナゾリン誘導体の製造方法 |
| WO2003064399A1 (fr) * | 2002-01-28 | 2003-08-07 | Ube Industries, Ltd. | Procede de production de derive de quinazolin-4-one |
| CN101613356A (zh) * | 2009-07-23 | 2009-12-30 | 东南大学 | 喹唑啉类四环衍生物及制备方法和在制药中的应用 |
| CN102898384A (zh) * | 2012-08-14 | 2013-01-30 | 邓俐丽 | 制备吉非替尼的中间体及所述中间体的制备方法 |
Non-Patent Citations (4)
| Title |
|---|
| Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7- dimethoxyquinazoline (PD153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor;Alexander J. Bridges等;《J. Med. Chem.》;19960105;第39卷(第1期);第267-276页 * |
| 硝酸铜硝化水杨酸甲酯的绿色硝化方法研究;李霞等;《精细化工中间体》;20091231;第39卷(第6期);第40-43页 * |
| 磷酸二氢钾催化下甲苯的选择性硝化;刘丽荣等;《含能材料》;20080229;第16卷(第1期);第63-65页 * |
| 芳香烃清洁硝化催化剂;丁春丽等;《化工环保》;20041231;第24卷(第5期);第361-366页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103288757A (zh) | 2013-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101863844A (zh) | 6,7-取代基-4-苯胺类喹唑啉的合成方法 | |
| CN105461704A (zh) | 一种依匹哌唑的制备方法 | |
| CN103288757B (zh) | 6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法 | |
| CN104945332A (zh) | 埃罗替尼的制备方法 | |
| US20230219990A1 (en) | Method for synthesizing c-nucleoside compound | |
| CN114751872A (zh) | 一种柱[5]芳烃n-杂环卡宾类催化剂及其制备方法和应用 | |
| CN102093289A (zh) | 布南色林中间体的制备新方法 | |
| CN103804432B (zh) | 基于二茂铁的双功能化胺‑硫脲有机催化剂及其制备方法和应用 | |
| CN1680325B (zh) | 吡啶衍生物的生产方法 | |
| CN101798289B (zh) | 一种埃罗替尼中间体的制备方法 | |
| CN103254183B (zh) | 阿法替尼的制备方法 | |
| CN103788010A (zh) | 非布索坦中间体及其制备方法 | |
| CN102757350A (zh) | 厄罗替尼中间体3-氨基苯乙炔的制备方法 | |
| CN103265497A (zh) | 一种替尼类抗肿瘤药合成所需中间体4-氯-6-氨基-7-羟基喹唑啉及其制备方法 | |
| CN102115446B (zh) | 一种催化合成手性姜黄素类似物的方法 | |
| CN105330590B (zh) | 西他沙星五元环侧链中间体的制备方法 | |
| CN110483323B (zh) | 一种不对称酰亚胺类化合物的制备方法 | |
| CN106279240B (zh) | 一种用于羰基保护的方法 | |
| Cheng et al. | A mild and efficient aza-Diels–Alder reaction of N-benzhydryl imines with trans-1-methoxy-2-methyl-3-trimethylsiloxybuta-1, 3-diene catalyzed by Yb (OTf) 3 | |
| CN103476745B (zh) | 含有磺酸基的二胺化合物及其制造方法 | |
| CN102199142B (zh) | 3h-1,2-苯并二磺酚-3-硫酮及其衍生物的制备方法 | |
| Sergeeva et al. | First stereoselective pinacol coupling in the [2.2] paracyclophane series | |
| CN106699777B (zh) | 一种杂环类化合物及合成方法 | |
| CN113861086B (zh) | 含硫γ, γ-双芳胺丁酰胺化合物的合成方法 | |
| CN112142663B (zh) | （s）-1-苯基-1,2,3,4-四氢异喹啉的合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200103 Address after: 629000 Suining innovation industrial park planning area, Sichuan Province Patentee after: SUINING YUEFENG STAINLESS STEEL CO., LTD. Address before: 215000 Jiangsu Province, Suzhou City Industrial Park Commercial Plaza Building 1 room 1305 Lianfeng Co-patentee before: Xu Xuenong Patentee before: Suzhou Mingyue Medical Technology Co., Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20200608 Address after: 233700 No.9, Niushi West Lane, Beimen, Cuihu garden, Chengguan Town, Guzhen County, Bengbu City, Anhui Province Patentee after: Guzhen Kean Chuangbing Information Technology Co., Ltd Address before: 629000 Suining innovation industrial park planning area, Sichuan Province Patentee before: SUINING YUEFENG STAINLESS STEEL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201030 Address after: No.369, Changjiang street, juancheng County, No. 26, sunbin North Road, juancheng County, Heze City, Shandong Province Patentee after: JUANCHENG PEOPLE'S Hospital Address before: 233700 No.9, Niushi West Lane, Beimen, Cuihu garden, Chengguan Town, Guzhen County, Bengbu City, Anhui Province Patentee before: Guzhen Kean Chuangbing Information Technology Co., Ltd |
|
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of 6-amino-7-hydroxy-3,4-dihydroquinazoline-4-one Effective date of registration: 20220222 Granted publication date: 20150701 Pledgee: Laishang Bank Co.,Ltd. Heze juancheng sub branch Pledgor: JUANCHENG PEOPLE'S Hospital Registration number: Y2022980001744 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |